论文部分内容阅读
目的 探讨血清髓鞘碱性蛋白 (MBP)测定在肝硬化患者脑部损害中的诊断意义。方法 采用酶联免疫吸附法定量测定肝硬化患者血清MBP水平。结果 62例肝硬化患者血清MBP为1.17(0.46～13.09) μg/L,高于正常对照组1.00(0.50～1.32) μg/L(P<0.01)。其中亚临床型和临床型肝性脑病组为13.60(10.54～20.28) μg/L ,高于无肝性脑病组[1.00(0.44～7.98) μg/L] ;按肝功能Child分级 ,A级[0.44(0.70～1.02) μg/L]、B级[1.17(0.74～4.39) μg/L]、C级[15.17(13.00～28.11) μg/L]之间MBP水平有差异。结论 血清MBP测定对临床上诊断亚临床型或早期肝性脑病有一定价值。
Objective To investigate the diagnostic significance of serum MBP determination in patients with liver cirrhosis. Methods Serum MBP levels were measured by enzyme-linked immunosorbent assay in cirrhotic patients. Results The serum MBP in 62 patients with cirrhosis was 1.17 (0.46 ~ 13.09) μg / L, which was higher than that of the normal control group (1.00 ~ 0.32) μg / L (P <0.01). The subclinical and clinical hepatic encephalopathy group was 13.60 (10.54 ~ 20.28) μg / L, higher than that of no hepatic encephalopathy group [1.00 (0.44 ~ 7.98) μg / L] 0.44 (0.70 ~ 1.02) μg / L], level B [1.17 (0.74 ~ 4.39) μg / L] and level C [15.17 (13.00 ~ 28.11) μg / L]. Conclusions The determination of serum MBP has clinical value in diagnosing subclinical or early hepatic encephalopathy.